Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma
- 204 Downloads
Concurrent chemoradiotherapy (CCRT) showed a significant improvement in disease control and clinical outcome in patients with intermediate and locoregionally advanced nasopharyngeal carcinoma (NPC) (stage II, III and IVA+B). However, there has been debate about the contribution and application of additional adjuvant chemotherapy (AC) to a CCRT regime. This study aims to evaluate the additional value of AC in the treatment of intermediate and locally advanced NPC with regard to toxicity and clinical outcomes. A total of 189 patients with American Joint Committee on Cancer (AJCC) stage II to stage IVB NPC were retrospectively identified. Patient characteristics, toxicity, compliance with treatment and clinical outcomes, including response to treatment, overall survival (OS), progression-free survival (PFS), relapse-free survival (RFS), freedom from local recurrence (FLR) and freedom from distant metastasis (FDM), were analyzed. The overall response rate of CCRT and CCRT/AC groups was 97.92 % and 97.83 %, respectively (P = 0.643). The 5-year OS rate was 68.2 % in the CCRT group and 75.9 % in the CCRT/AC group (P = 0.53). The 5-year PFS rate was 66.7 % and 71.4 % in CCRT and CCRT/AC groups, respectively (P = 0.96). This study showed no evidence of an additional value of AC in CCRT treatment in disease control and clinical outcomes in patients with locally advanced NPC in endemic regions. Moreover, three additional cycles of AC after CCRT appeared to be poorly tolerated in patients. Therefore, AC should not be routinely used for treatment, although clinical trials may be justified.
KeywordsNasopharyngeal carcinoma Concurrent chemoradiotherapy Adjuvant chemotherapy
We thank Dr. David Lopes, from the Department of Haemato-oncology, Conde S. Januario General Hospital, Macao SAR, and Dr. Weihua Wang from the Radiotherapy Center, Kiangwu Hospital, Macao SAR, for assistance in data collection.
Conflicts of interest
The authors have no potential conflicts of interest to be disclosed.
- 3.Al-Saraf M, LeBlanc M, Giri PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol. 1998;16:1310–7.Google Scholar
- 10.Liu A, Swisher-McClure S, Millar LB, et al. Proton therapy for head and neck cancer: current applications and future directions. Transl Cancer Res. 2012;1:255–63.Google Scholar
- 11.Giap H, Giap B. Historical perspective and evolution of charged particle beam therapy. Transl Cancer Res. 2012;1(3):127–36.Google Scholar
- 13.Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163–71. Epub 2011 Dec 7.PubMedCrossRefGoogle Scholar
- 14.Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on Cancer) cancer staging manual. 7th ed. New York: Springer; 2010. p. 41–56.Google Scholar
- 15.Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization classification of tumours. Pathology and genetics of head and neck tumors. Lyon: IARC Press; 2005.Google Scholar
- 21.Nakagawa K, Tsurutani J. Perspectives in drug development for cancer therapy in Asia. Chin Clin Oncol. 2012;1:17.Google Scholar
- 25.Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 2008;71:1356–66.PubMedCrossRefGoogle Scholar
- 26.Zhang L, Zhao C, Ghimire Y, et al. The role of concurrent chemoradiation in the treatment of locally advanced nasopharyngeal carcinoma among endemic area: a meta-analysis of the phase III randomized trials. J Clin Oncol. 2008; 26:6032. (Available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstracted =34253, accessed June 3, 2009).Google Scholar
- 27.David GP, Kei-Kian A, David MB, et al. NCCN clinical practice guidelines in oncology——Head and Neck Cancers, Version I, 2012, pp 30–32.Google Scholar
- 28.Wee J. Eng Huat Tan, Bee Choo Tai, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–8.PubMedCrossRefGoogle Scholar
- 30.Rassi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincritine, cyclophosphamide, and doxorubicin after radiotherapy in local–regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988;16:1401–10.Google Scholar